COMMUNIQUÉS West-GlobeNewswire

Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update
11/05/2026
– LOQTORZI ® net revenue of $11.8 million in Q1 2026 – – Patient accrual complete for 1L HCC Phase 2 randomized clinical trial for anti-IL27 casdozokitug, timing for data readouts tracking to projections – – Tagmokitug [...]
Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results
11/05/2026
Delivered Q1 2026 Total Revenues of $149.4 Million Results include 28% YoY Increase in Net Product Revenues from FIRDAPSE® & AGAMREE® Reported Cash and Cash Equivalents of $755.9 Million and No Funded Debt as of [...]
Sangamo Therapeutics Announces First Quarter 2026 Earnings Call
11/05/2026
RICHMOND, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (OTCQB Venture Market: SGMO), a genomic medicine company today announced that the company has scheduled the release of its first quarter 2026 [...]
CG Oncology’s Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC
11/05/2026
- First results from CORE-008 Cohort CX Phase 2 Trial evaluating intravesical combination therapy in High-Risk BCG-Exposed and BCG-Unresponsive patients to be presented - - Visit CG Oncology at booth #3051 - DALLAS, May [...]
Sanara MedTech Inc. Reports First Quarter 2026 Financial Results (Unaudited)
11/05/2026
Net Revenue Growth of 19% and Net Profitability from Continuing Operations of $0.04 Per Fully Diluted Share for the Quarter FORT WORTH, TX, May 11, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” “Sanara MedTech [...]
Oculis Reports Q1 2026 Financial Results and Provides Company Update
11/05/2026
Pipeline Advancing as Planned, Leading with OCS-01 Key Milestone Completion of LPLV in Both DIAMOND Phase 3 Trials; Data Readout on Track for June 2026 Licaminlimab PREDICT-1 Trial in Active Site Recruitment Phase, [...]
SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update
11/05/2026
Completed transformative acquisition of PXL-770, (now SCY-770), an innovative, highly selective, direct AMPK activator for the treatment of autosomal dominant polycystic kidney disease (ADPKD) A Phase 2 proof-of-concept [...]
Pharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares
11/05/2026
ZUG, Switzerland, May 11, 2026 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs [...]
CVRx Reports First Quarter 2026 Financial and Operating Results
11/05/2026
MINNEAPOLIS, May 11, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions [...]
Harrow Announces First Quarter 2026 Financial Results
11/05/2026
First Quarter 2026 and Selected Highlights: VEVYE ® delivered record new and total prescription performance (despite an approximate 18% decline in the overall branded dry eye category) VEVYE demand growth on track to [...]
Outset Medical to Present at RBC Global Healthcare Conference
11/05/2026
SAN JOSE, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis with less [...]
Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results
11/05/2026
On track for regulatory submission of MGX-001 to advance global clinical program, including investigational new drug application (“IND”) in 4Q 2026 Publication in Nature Structural & Molecular Biology highlights [...]
Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights
11/05/2026
Successfully completed chronic toxicology studies for icovamenib, providing the nonclinical support for advancing to chronic clinical dosing, beyond the 12-week clinical dosing that has been used to date Topline data [...]
Ceribell Reports First Quarter 2026 Financial Results
11/05/2026
SUNNYVALE, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological [...]
Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates
11/05/2026
Announced strategic collaboration with Mayo Clinic, focused on improving care in type 1 diabetes and accelerating development of SC451 Continued progress toward starting SC451 Phase 1 trial later this year, including [...]
Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update
11/05/2026
Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) is progressing well with the interim analysis [...]
CORRECTION – Human Appeal Launches Hajj Step Challenge, Turning Steps into a Lifeline
11/05/2026
Participants challenged to walk 10,000 steps a day during the 10 most sacred days of the Islamic Calendar, raising funds to deliver vital meals to those in need In a release issued earlier on Monday, May 11, under the [...]
Solana Company to Release First Quarter 2026 Operating Results on May 15, 2026
11/05/2026
NEWTOWN, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ: HSDT) (the “Company” or “HSDT”), a publicly listed company, today announced that the Company will release its first quarter operating results on [...]
Abivax Announces Results of its May 11, 2026 Annual General Meeting
11/05/2026
Abivax Announces Results of its May 11, 2026 Annual General Meeting PARIS, France – May 11, 2026 – 10:05 pm CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical- [...]

Pages